Greenwich LifeSciences, Inc.

Healthcare · Biotechnology · United States

Last price 19 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 278.89M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients. The company also develops FLAMINGO-01, which is in Phase IIb and 3 Phase I clinical trial designed to evaluate the safety and efficacy of GLSI-100 in HER2 positive breast cancer patients. Greenwich LifeSc...